Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
SSRP1 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q08945 |
|---|---|
| Clone Names | 100507283 |
| Gene ID | 6749 |
|---|---|
| Other Names | FACT complex subunit SSRP1, Chromatin-specific transcription elongation factor 80 kDa subunit, Facilitates chromatin transcription complex 80 kDa subunit, FACT 80 kDa subunit, FACTp80, Facilitates chromatin transcription complex subunit SSRP1, Recombination signal sequence recognition protein 1, Structure-specific recognition protein 1, hSSRP1, T160, SSRP1, FACT80 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | SSRP1 |
|---|---|
| Synonyms | FACT80 |
| Function | Component of the FACT complex, a general chromatin factor that acts to reorganize nucleosomes. The FACT complex is involved in multiple processes that require DNA as a template such as mRNA elongation, DNA replication and DNA repair. During transcription elongation the FACT complex acts as a histone chaperone that both destabilizes and restores nucleosomal structure. It facilitates the passage of RNA polymerase II and transcription by promoting the dissociation of one histone H2A-H2B dimer from the nucleosome, then subsequently promotes the reestablishment of the nucleosome following the passage of RNA polymerase II. The FACT complex is probably also involved in phosphorylation of 'Ser-392' of p53/TP53 via its association with CK2 (casein kinase II). Binds specifically to double- stranded DNA and at low levels to DNA modified by the antitumor agent cisplatin. May potentiate cisplatin-induced cell death by blocking replication and repair of modified DNA. Also acts as a transcriptional coactivator for p63/TP63. |
| Cellular Location | Nucleus. Nucleus, nucleolus. Chromosome. Note=Colocalizes with RNA polymerase II on chromatin. Recruited to actively transcribed loci {ECO:0000250|UniProtKB:Q05344} |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is a subunit of aheterodimer that, along with SUPT16H, forms chromatintranscriptional elongation factor FACT. FACT interacts specificallywith histones H2A/H2B to effect nucleosome disassembly andtranscription elongation. FACT and cisplatin-damaged DNA may becrucial to the anticancer mechanism of cisplatin. This encodedprotein contains a high mobility group box which most likelyconstitutes the structure recognition element forcisplatin-modified DNA. This protein also functions as aco-activator of the transcriptional activator p63. An alternativelyspliced transcript variant of this gene has been described, but itsfull-length nature is not known.
References
Zeng, S.X., et al. Mol. Cell. Biol. 30(4):935-947(2010)Hautbergue, G.M., et al. Curr. Biol. 19(22):1918-1924(2009)Hu, J., et al. J. Virol. 83(21):11051-11063(2009)Kumari, A., et al. J. Cell. Biochem. 108(2):508-518(2009)Okada, M., et al. Mol. Biol. Cell 20(18):3986-3995(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
